tuned in to tips

New Houston-based app tips the scales in favor of musicians and fans

A Houston entrepreneur has created a platform that puts artists first. Photo courtesy of PickleJar

Like so many business owners, Jeff James' inspiration for his innovative new music app PickleJar, came out of sheer necessity. Sitting in a bar in the buzzy Broadway district in Nashville, Tennessee, James, a serial entrepreneur, realized there had to be a better way to tip performing musicians.

"This young girl comes through the crowd carrying a Yeti bucket asking for 20 dollars for the band," James tells CultureMap. With no cash on hand, James donated via Square. "Sixty dollars later, I had so many questions: would she remember my name? Would she remember my songs? There's gotta be a better way to do this."

James, a former radio DJ and record label veteran, started scribbling his idea for a musician tipping app on a napkin. Two years later, PickleJar was sparked, James says, because "every musician we spoke to hates the way they're paid on these apps like Venmo and Facebook."

Pushing an "artist first," mission statement, PickleJar ensures that every musician utilizing the app keeps 100 percent of the money — something unheard of when James started the process two years ago. Fans donate to musicians on the app, and in turn, get five times that tip in proprietary digital currency called Pick Coins.

"If you tip 100 dollars to a musician, you get 500 Pick Coins," explains James, "that goes to buying tickets, merch, or VIP experiences on our app." Another artist-first perk: The artist also gets 500 Pick Coins in that scenario.

With its own e-commerce platform, PickleJar allows fans to use these Pick Coins for experiences, and musicians to use them for much-needed equipment. PickleJar has partnered with Austin-based Strait Music Company, which will provide musicians with instruments and gear. Musicians can create their own wish lists so that fans can directly contribute to the desired gear.

Fittingly, the company has partnered with local venues for themed nights. Buzzy bar McIntyre's Downtown will feature a tip-worthy Texas artist every Wednesday night in its PickLounge.

PickleJar also allows musicians to livestream. "On Facebook Live, data shows that only about eight to 10 percent of an artist's audience know they're live. On top of that, Facebook takes 30 to 40 percent of the tips." With PickleJar, 100 percent of an artists fans will be notified when the artists in livestreaming.

Fans can even donate directly to a musician's nonprofit of choice, something happening now during Hurricane Ida relief efforts. Numerous artists on PickleJar are raising funds for Ida assistance, James notes. "We really believe that a 'gratitude economy' is emerging," he says. "We wanted to create the easiest way possible for fans to say thank you."

That thank-you option also means fans can send direct messages, notes, and even pictures on the app, which, James acknowledges with a chuckle, could get very interesting.

Another musician-first nuance not found on other apps: PickleJar allows for "smart" splits, so that musicians are appropriately compensated for their specific contribution. An artist who wrote songs and drove the van to a gig, for example, can be funneled a higher percentage of tips than bandmates who contributed less.

James and his Houston-based tech team are also working on a TV channel on streaming devices, dubbed PickleJar Plus.

While one might be tempted to assume PickleJar is meant for those gig-to-gig, struggling musicians, James assures that the app is meant for every level, which he breaks down accordingly:

  • "Never-evers": These folks will never get signed, but use the app to get better
  • "Got talent, not signed": Artists can use PickleJar to build audiences and crowdfund
  • "I'm signed/labeled": Here, signed artists curate setlists which can be monetized via tips
  • "Idols": These artists are already brands. "Kenny Chesney can use this to make sure every dollar goes to a nonprofit," says James. Chesney's team can watch a meter, and when donations hit a specific dollar amount, Chesney can reward fans with their favorite song."

If all this seems to point to James one day managing and representing artists, James says that idea is not entirely off. PickleJar could one day be the world's biggest independent record label, he acknowledges, by the way it allows indies to promote themselves.

"We were in a meeting and the guy says, 'you're gonna change the entertainment world forever,'" James, recalls. "We hope so. We just want to build a relationship with artists — and put them first."

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted